Page last updated: 2024-08-16

temazepam and halazepam

temazepam has been researched along with halazepam in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Babbini, M; Barbaro, AM; Bartoletti, M; Biagi, GL; Borea, PA; Gaiardi, M; Guerra, MC1
Johnston, GA; Maddalena, DJ1
Karplus, M; So, SS1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1

Other Studies

4 other study(ies) available for temazepam and halazepam

ArticleYear
Rm values and structure-activity relationship of benzodiazepines.
    Journal of medicinal chemistry, 1980, Volume: 23, Issue:2

    Topics: Animals; Benzodiazepines; Chromatography, Thin Layer; Conflict, Psychological; Exploratory Behavior; Models, Biological; Rats; Solubility; Structure-Activity Relationship

1980
Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks.
    Journal of medicinal chemistry, 1995, Feb-17, Volume: 38, Issue:4

    Topics: Binding Sites; Ligands; Neural Networks, Computer; Predictive Value of Tests; Receptors, GABA-A; Structure-Activity Relationship

1995
Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors.
    Journal of medicinal chemistry, 1996, Dec-20, Volume: 39, Issue:26

    Topics: Algorithms; Benzodiazepines; Models, Genetic; Nerve Net; Protein Binding; Receptors, GABA-A; Structure-Activity Relationship

1996
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004